Domača stranABVX • EPA
add
Abivax SA
Prejšnji trg. dan.
8,20 €
Dnevni razpon
8,11 € - 8,50 €
Letni razpon
8,02 € - 15,42 €
Tržna kapitalizacija
509,56 mio. EUR
Povprečni obseg
20,03 tis.
Razm. P/E
-
Dividendna donosnost
-
Primarna borza
EPA
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 3,39 mio. | 201,87 % |
Stroški poslovanja | 43,39 mio. | 119,55 % |
Čisti dohodek | −40,82 mio. | −57,14 % |
Čista dobičkovnost prihodkov | −1,20 tis. | 47,94 % |
Earnings per share | — | — |
EBITDA | −39,91 mio. | −114,56 % |
Efektivna davčna stopnja | — | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 222,32 mio. | 94,37 % |
Skupna sredstva | 284,49 mio. | 66,29 % |
Skupne obveznosti | 158,02 mio. | 74,43 % |
Celoten lastniški kapital | 126,47 mio. | — |
Shares outstanding | 62,92 mio. | — |
Razmerje P/B | 4,08 | — |
Donosnost sredstev | −35,15 % | — |
Donosnost kapitala | −41,69 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (EUR) | jun. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | −40,82 mio. | −57,14 % |
Denar iz dejavnosti | −42,59 mio. | −208,62 % |
Denar iz naložb | 6,73 mio. | 886,10 % |
Denar iz financiranja | 20,16 mio. | −65,46 % |
Neto sprememba denarnih sredstev | −14,81 mio. | −133,88 % |
Prost denarni tok | −21,07 mio. | −45,88 % |
Vizitka
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has one program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, MA. Abivax’s R&D work is conducted at its research center based in Montpellier, France. Wikipedia
Generalni direktor
Datum ustanovitve
4. dec. 2013
Spletno mesto
Zaposleni
62
